Tesla
TSLA
Apple
AAPL
Meta Platforms
META
Microsoft
MSFT
Petroleo Brasileiro SA Petrobras
PBR
US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 6.470
- -0.140-2.12%
Close Mar 21 16:00 ET
- 6.380
- -0.090-1.39%
Post 19:32 ET
625.53MMarket Cap-13.77P/E (TTM)
6.620High6.365Low3.74MVolume6.520Open6.610Pre Close24.21MTurnover5.08%Turnover RatioLossP/E (Static)96.68MShares7.39052wk High6.28P/B476.63MFloat Cap2.30052wk Low--Dividend TTM73.67MShs Float10.620Historical High--Div YieldTTM3.86%Amplitude0.460Historical Low6.468Avg Price1Lot Size
About Trevi Therapeutics Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
Company Profile
SymbolTRVI
Company NameTrevi Therapeutics
Listing DateMay 7, 2019
Issue Price10.00
Founded2011
CEOMs. Jennifer L. Good
MarketNASDAQ
Employees26
Fiscal Year Ends12-31
Address195 Church Street,16th floor
CityNew Haven
ProvinceConnecticut
CountryUnited States of America
Zip Code06510
Phone1-203-304-2499
Company Executives
- Name
- Position
- Salary
- Jennifer L. Good
- President, Chief Executive Officer and Director
- 1.69M
- Dr. Thomas R. Sciascia,M.D.
- Chief Scientific Officer
- 977.13K
- Lisa Delfini
- Chief Financial Officer
- --
- Dr. James V. Cassella,PhD
- Chief Development Officer
- 112.95K
- Farrell Simon
- Chief Commercial Officer
- --
- Christopher Galletta
- Controller and Principal Accounting Officer
- --
- Dr. David P. Meeker,M.D.
- Chairman of the Board
- 135.45K
- Michael T. Heffernan, R.Ph.
- Independent Director
- 127.95K
- Edward T. Mathers
- Independent Director
- 110.45K
- Dominick C. Colangelo
- Independent Director
- 120.45K
- Anne M. Vanlent
- Independent Director
- 127.95K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.